BKIE - ETF AI Analysis

Top Page

BNY Mellon International Equity ETF (BKIE)

Rating:66Neutral

Price Target:―

BKIE, the BNY Mellon International Equity ETF, has a solid overall rating driven mainly by high-quality global leaders like Novartis, AstraZeneca, HSBC, and Toyota, which show strong financial health, positive earnings commentary, and generally supportive technical and valuation signals. These strengths are partly offset by some holdings such as Roche and Shell, where valuation concerns, potential overbought or short-term technical weakness, and growth challenges introduce added risk. The fund is also notably exposed to large non-U.S. financial, healthcare, and industrial names, so sector and regional concentration in these areas is an important risk factor to keep in mind.

Positive Factors

Low Expense Ratio

The fund charges a very low fee, which helps investors keep more of their returns over time.

Broad International Diversification

Holdings spread across many countries such as Japan, the UK, the U.S., and Europe help reduce the impact of weakness in any single market.

Solid Recent Performance

The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.

Negative Factors

Heavy Financials Exposure

A large portion of the portfolio is in financial stocks, which can make the fund more sensitive to changes in interest rates and banking conditions.

Mixed Results Among Top Holdings

While some leading positions like ASML, Toyota, and Siemens have performed strongly, others such as Nestlé, SAP, and Royal Bank of Canada have been weaker and may drag on returns.

Limited Sector Balance

Compared with its sizable financial and industrial stakes, the fund has relatively smaller allocations to areas like technology and real estate, which may reduce exposure to some growth opportunities.

BKIE vs. SPDR S&P 500 ETF (SPY)

AUM1.29B

RegionDeveloped Markets

Expense Ratio0.04%

Beta0.71

IssuerBNY Mellon

Inception DateApr 22, 2020

Dividend Yield2.84%

Asset ClassEquity

Index TrackedSolactive GBS Developed Markets ex United States Large & Mid Cap Index - Benchmark TR Gross

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume49,317

30 Day Avg. Volume59,731

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

109.82

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering972

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

BKIE Summary

BKIE is the BNY Mellon International Equity ETF, which tracks the Solactive GBS Developed Markets ex United States Large & Mid Cap Index. It invests in a wide range of companies outside the U.S., across countries like Japan, the UK, and Germany, and sectors such as financials, industrials, and technology. Well-known holdings include ASML, Toyota, Nestlé, and AstraZeneca. Someone might invest in BKIE to diversify beyond the U.S. and tap into long-term growth in global markets with one simple fund. A key risk is that international stocks can be volatile and move differently than the U.S. market.

How much will it cost me?The BNY Mellon International Equity ETF (BKIE) has an expense ratio of 0.04%, which means you’ll pay $0.40 per year for every $1,000 invested. This is lower than average because it’s passively managed, tracking an index rather than relying on active management strategies.

What would affect this ETF?BKIE's focus on developed markets outside the U.S. could benefit from economic recovery in Europe and Asia, as well as growth in sectors like financials and technology, which are heavily weighted in the ETF. However, potential risks include geopolitical tensions, regulatory changes in key regions, or slower-than-expected growth in international markets, which could negatively impact top holdings like ASML and Nestlé. Additionally, currency fluctuations could affect returns for U.S.-based investors.

BKIE Top 10 Holdings

BKIE leans heavily on international blue chips, with chipmaker ASML acting as a key engine of growth thanks to its rising momentum. Health care giants like Roche, Novartis, and AstraZeneca are also pulling their weight, giving the fund a strong defensive backbone that’s been steadily climbing. Financials such as HSBC and Mitsubishi UFJ add another leg of support, while Royal Bank of Canada looks more mixed, occasionally losing steam. With broad exposure across Europe, Japan, and other developed markets outside the U.S., the ETF is globally diversified but tilted toward financials and health care.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ASML	ASML Holding NV	2.14%	$27.47M	€482.60B	75.59%	76 Outperform
ROG	Roche Holding AG	1.28%	$16.41M	CHF295.18B	44.93%	73 Outperform
HSBA	HSBC Holdings	1.25%	$16.14M	£221.80B	53.24%	80 Outperform
NOVN	Novartis AG	1.22%	$15.64M	CHF246.66B	31.24%	80 Outperform
AZN	AstraZeneca	1.18%	$15.24M	$322.49B	25.73%	80 Outperform
NESN	Nestlé SA	1.07%	$13.70M	CHF209.77B	11.07%	71 Outperform
7203	Toyota Motor	0.99%	$12.72M	¥47.65T	35.63%	80 Outperform
RY	Royal Bank Of Canada	0.92%	$11.84M	$239.87B	47.41%	75 Outperform
SHEL	Shell (UK)	0.90%	$11.61M	£167.70B	14.03%	73 Outperform
SIE	Siemens	0.84%	$10.85M	€186.87B	12.25%	74 Outperform

BKIE Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

96.28

Positive

100DMA

92.75

Positive

200DMA

88.45

Positive

Market Momentum

MACD

1.47

Positive

RSI

67.32

Neutral

STOCH

89.72

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BKIE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 99.47, equal to the 50-day MA of 96.28, and equal to the 200-day MA of 88.45, indicating a bullish trend. The MACD of 1.47 indicates Positive momentum. The RSI at 67.32 is Neutral, neither overbought nor oversold. The STOCH value of 89.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BKIE.

BKIE Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
BKIE	―	―	$1.29B	0.04%	66 Neutral
GSIE	―	―	$5.47B	0.25%	66 Neutral
LVHI	―	―	$4.62B	0.40%	70 Outperform
IMTM	―	―	$3.84B	0.30%	68 Neutral
INTF	―	―	$3.30B	0.16%	65 Neutral
IDMO	―	―	$3.29B	0.25%	68 Neutral

Performance Comparison

BKIE

BNY Mellon International Equity ETF

101.44

26.52

35.40%

GSIE

Goldman Sachs ActiveBeta International Equity ETF

―

LVHI

Legg Mason International Low Volatility High Dividend ETF

―

IMTM

iShares MSCI Intl Momentum Factor ETF

―

INTF

iShares MSCI Intl Multifactor ETF

―

IDMO

Invesco S&P International Developed Momentum ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents